ProBNP 1-108 is resistant to degradation and activates guanylyl cyclase-A with reduced potency

Clinical Chemistry

Volumn 57, Issue 9, 2011, Pages 1272-1278

  Dickey, Deborah M ^a   Potter, Lincoln R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE RECEPTOR; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLYL CYCLASE A; IODINE 125; RECEPTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION;

CYCLIC GMP; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; KIDNEY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN PRECURSORS; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 80052237890     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.169151     Document Type: Article

References (33)

1. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009:341-66.
2. Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacol Ther 2011;130:71-82.
3. Wang Y, de Waard MC, Sterner-Kock A, Stepan H, Schultheiss HP, Duncker DJ, Walther T. Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail 2007;9:548-57. (Pubitemid 46702821)
4. Koller KJ, Lowe DG, Bennett GL, Minamino N, Kangawa K, Matsuo H, Goeddel DV. Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP). Science (Wash DC) 1991;252:120-3. (Pubitemid 21916951)
5. Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011;278:1808-17.
6. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol 2011;301:H12-20.
7. Rame JE, Tam SW, McNamara D, Worcel M, Sabolinski ML, Wu AH, Dries DL. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail 2009;2:541-8.
8. Wang W, Liao X, Fukuda K, Knappe S, Wu F, Dries DL, et al. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res 2008;103:502-8.
9. Sawada Y, Suda M, Yokoyama H, Kanda T, Sakamaki T, Tanaka S, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem 1997;272:20545-54. (Pubitemid 27355612)
10. Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010;56:1166-76.
11. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129-35. (Pubitemid 34028197)
12. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9. (Pubitemid 36836080)
13. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866-73. (Pubitemid 46744242)
14. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner EA. Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 1993;76:832-8. (Pubitemid 23110823)
15. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8. (Pubitemid 46349497)
16. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160-6.
17. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006;52:82-7. (Pubitemid 43032470)
18. Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258-64.
19. Dickey DM, Yoder AR, Potter LR. A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem 2009;284:19196-202.
20. Dickey DM, Burnett JC Jr, Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008;283:35003-9.
21. Dickey DM, Potter LR. Human B-type natriuretic peptide is not degraded by meprin A. Biochem Pharmacol 2010;80:1007-11.
22. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr. Immunoreactivity and guanosine 3′,5′- cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007;49:1114-9. (Pubitemid 351664304)
23. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
24. Goetze JP, Kastrup J, Rehfeld JF. The paradox of increased natriuretic hormones in congestive heart failure patients: does the endocrine heart also fail in heart failure? Eur Heart J 2003;24:1471-2. (Pubitemid 37010575)
25. Garbers DL, Koesling D, Schultz G. Guanylyl cyclase receptors. Mol Biol Cell 1994;5:1-5. (Pubitemid 24062027)
26. Semenov AG, Seferian KR, Tamm NN, Artem'eva MM, Postnikov AB, Bereznikova AV, et al. Human pro-B-type natriuretic peptide is processed in the circulation in a rat model. Clin Chem 2011;57:883-90.
27. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91-6. (Pubitemid 23027559)
28. Vanneste Y, Pauwels S, Lambotte L, Deschodt-Lanckman M. In vivo metabolism of brain natriuretic peptide in the rat involves endopeptidase 24.11 and angiotensin converting enzyme. Biochem Biophys Res Commun 1990;173:265-71.
29. Jiang J, Pristera N, Wang W, Zhang X, Wu Q. Effect of sialylated O-glycans in pro-brain natriuretic peptide stability. Clin Chem 2010;56:959-66.
30. Dickey DM, Potter LR. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CDNP, are resistant to proteolytic inactivation. J Mol Cell Cardiol 2011;51:67-71.
31. Ralat LA, Guo Q, Ren M, Funke T, Dickey DM, Potter LR, Tang WJ. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem 2011;286:4670-9.
32. Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 2004;50:1503-10. (Pubitemid 39121217)
33. Mukoyama M, Nakao K, Saito Y, Ogawa Y, Hosoda K, Suga S, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 1990;323:757-8. (Pubitemid 20288962)